Citations

Clear

203 citation(s) found for "Alberts, Steven".

Gemcitabine Plus Cisplatin in Advanced Pancreatic Cancer
McWilliams, Robert R. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 16, 2007 | Volume: 25 | Issue: 9 | Pages: 1142-1142

10.1200/jco.2006.09.0035 | PMID 17369580 Get It

Evolving Role of Chemotherapy in Resected Liver Metastases
Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | October 30, 2006 | Volume: 24 | Issue: 31 | Pages: 4952-4953

10.1200/jco.2006.07.9236 | PMID 17075111 Get It

Differences in Cancer Incidence among Indians in Alaska and New Mexico and U.S. Whites, 1993-2002
Kelly, Janet J., Lanier, Anne P., Wiggins, Charles L. , Alberts, Steven R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | August 8, 2006 | Volume: 15 | Issue: 8 | Pages: 1515-1519

10.1158/1055-9965.epi-05-0454 | PMID 16896042 Get It

Abstract Cancer incidence for American Indians and Alaska Natives is typically reported as a single rate for all U.S. indigenous populations combined. Previously reported combined rates suggest that American Indians and Alaska Natives have lower cancer incidence rates compared with the U.S. population. Alaska Native people comprise three major ethnic groups: Eskimo, Indian, and Aleut people. We examined cancer incidence from only Alaska Indians and compared incidence rates with an American Indian population living in New Mexico. These data indicate striking differences in cancer patterns between two American Indian populations. Cancer data for the years 1993 to 2002 for American Indians of New Mexico and U.S. Whites are from the National Cancer Institute Surveillance, Epidemiology, and End Results Program Public-use data set. Data for Alaska Indians are from the Alaska Native Tumor Registry, which is also a Surveillance Epidemiology and End Results Program participant. Overall, cancer incidence rates for all sites combined in New Mexico Indian men and women were lower than U.S. White rates, whereas Alaska Indian men and women exceeded U.S. rates. In comparing Alaska and New Mexico Indians, we observed a 2.5-fold higher incidence of cancer among Alaska Indians. The largest differences between the two Indian populations were noted primarily in cancers associated with tobacco use, including cancers of the oral cavity/pharynx, esophagus (only in men), colon and rectum, pancreas, larynx (men), lung, prostate, and urinary bladder (men). Lung cancer rates in Alaska Indian men and women were 7 and 10 times those of New Mexico Indian men and women. (Cancer Epidemiol Biomarkers Prev 2006;15(8):1515–9)
Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial
Goldberg, Richard M. , Sargent, Daniel J. , Morton, Roscoe F., Fuchs, Charles S. , Ramanathan, Ramesh K., Williamson, Stephen K. , Findlay, B., Pitot, Henry C., Alberts, Steven R. , Sargent, Daniel J , Williamson, Stephen

Mayo Clinic

Journal of Clinical Oncology | July 18, 2006 | Volume: 24 | Issue: 21 | Pages: 3347-3353

10.1200/jco.2006.06.1317 | PMID 16849748 Get It

Purpose Previously, we reported results of Intergroup N9741, which compared standard bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leucovorin, plus oxaliplatin (FOLFOX4) and irinotecan plus oxaliplatin in patients with untreated metastatic colorectal cancer. High rates of grade ≥ 3 toxicity on IFL (resulting in some deaths) led us to reduce the starting doses of both irinotecan and FU by 20% (rIFL). This article compares rIFL with FOLFOX4. Patients and Methods The primary comparison was time to progression, with secondary end points of response rate (RR), overall survival, and toxicity. Results Three hundred five patients were randomly assigned. The North Central Cancer Treatment Group Data Safety Monitoring Committee interrupted enrollment at a planned interim analysis when outcomes crossed predetermined stopping boundaries. The results were significantly superior for FOLFOX4 compared with rIFL for time to progression (9.7 v 5.5 months, respectively; P < .0001), RR (48% v 32%, respectively; P = .006), and overall survival (19.0 v 16.3 months, respectively; P = .026). Toxicity profiles were not significantly different between regimens for nausea, vomiting, diarrhea, febrile neutropenia, dehydration, or 60-day all-cause mortality. Sensory neuropathy and neutropenia were significantly more common with FOLFOX4. Approximately 75% of patients in both arms received second-line therapy; 58% of rIFL patients received oxaliplatin-based second-line therapy, and 55% of FOLFOX4 patients received irinotecan-based regimens as second-line therapy. Conclusion FOLFOX4 led to superior RR, time to progression, and overall survival compared with rIFL. The survival benefit for FOLFOX4 observed in the earlier stage of the study was preserved with equal use of either irinotecan or oxaliplatin as second-line therapy.
Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer
Steensma, David P. , Molina, R, Sloan, Jeff A. , Nikcevich, Daniel A., Schaefer, Paul, Rowland, Kendrith M. , Dentchev, Todor, Novotny, Paul J. , Tschetter, Loren K., Hogan, Thomas F., Law, Amy , Loprinzi, Charles L. , Alberts, Steven R. , Steensma, David P

Mayo Clinic

Journal of Clinical Oncology | February 28, 2006 | Volume: 24 | Issue: 7 | Pages: 1079-1089

10.1200/jco.2005.02.7276 | PMID 16505427 Get It

Purpose To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia. Patients and Methods Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously (SC), followed by either standard weekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120K arm) SC every 3 weeks for 18 additional weeks. Results Three hundred sixty-five patients were enrolled. One hundred eighty-three patients were assigned to the 40K arm, and 182 were assigned to the 120K arm. There was no difference in the proportion of patients requiring transfusions during the study (23% in 40K arm and 18% in 120K arm, P = .22) or specifically during the maintenance phase (13% in 40K arm v 15% in 120K arm, P = .58). Patients randomly assigned to the 40K arm were more likely to have a ≥ 2 or ≥ 3 g/dL hemoglobin (Hb) increment, were more likely to have a drug dose held because of high Hb, and had higher mean end-of-study Hb levels. Toxicities, including thromboembolism, and overall survival were similar. Patients in the 40K arm had a higher global quality of life (QOL) at baseline for unclear reasons, whereas patients in the 120K arm had a greater global QOL improvement during the study, so end-of-study QOL was equivalent. Conclusion After three weekly doses of epoetin alfa 40,000 U, a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing QOL. The Hb increment is somewhat greater with continued weekly epoetin alfa. Lack of blinding as a result of different treatment schedules may have confounded results.
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
Horvath, William L., Sternfeld, William C., Goldberg, Richard M. , Mahoney, Michelle R., Dakhil, Shaker R. , Levitt, Ralph, Rowland, Kendrith M. , Nair, Suresh , Sargent, Daniel J. , Donohue, John H., Alberts, Steven R. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | October 18, 2005 | Volume: 23 | Issue: 36 | Pages: 9243-9249

10.1200/jco.2005.07.740 | PMID 16230673 Get It

Purpose Surgical resection of liver-only metastases from colorectal cancer has undergone extensive evaluation and review. The use of neoadjuvant chemotherapy to improve the likelihood of resection in disease that is not optimally resectable has not been as well studied. Patients and Methods Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4). Patients were periodically reassessed for resectability. Surgical response was classified as completely resectable (S-CR), partially resectable (S-PR), or unresectable (S-UR). Study design specified the accrual of 39 patients, with two or more S-CRs considered evidence of promising activity with respect to increasing the S-CR rate. Results Forty-two of 44 patients were assessable for this analysis. Twenty-five patients (60%) had tumor reduction by serial imaging. Seventeen patients (40%) underwent surgery (S-CR, n = 14; S-PR, n = 1; and S-UR, n = 2) after a median of 6 months of chemotherapy. With a median postsurgical follow-up of 22 months (range, 13 to 32 months), 11 recurrences have occurred in the 15 S-CR and S-PR patients. Median survival time was 26 months. Conclusion Our data suggest that FOLFOX4 has a high response rate (complete response, partial response, or reduction) in patients with liver-only metastases from colorectal cancer, allowing for successful resection of disease in a portion of patients initially not judged to be optimally resectable. However, a high recurrence rate after surgery was observed, which, in 73% of patients, involved the liver. Further trials are indicated based on the promising results observed in this trial.
OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer
Poston, Graeme J., Curley, Steven A. , Figueras, Juan, Haller, Daniel G. , Kunstlinger, F, Mentha, Gilles, Nordlinger, Bernard, Patt, Yehuda Z., Primrose, John , Rougier, Philippe, Ruers, Theo, Valls, Carlos, Vauthey, Nick Jean-Nicolas, Cornelis, Marleen, Kahan, James P., Adam, René , Alberts, Steven R. , Roh, Mark S. , Schmoll, Hans‐Joachim

Mayo Clinic

Journal of Clinical Oncology | September 28, 2005 | Volume: 23 | Issue: 28 | Pages: 7125-7134

10.1200/jco.2005.08.722 | PMID 16192596 Get It

Purpose Most patients with colorectal liver metastases present to general surgeons and oncologists without a specialist interest in their management. Since treatment strategy is frequently dependent on the response to earlier treatments, our aim was to create a therapeutic decision model identifying appropriate procedure sequences. Methods We used the RAND Corporation/University of California, Los Angeles Appropriateness Method (RAM) assessing strategies of resection, local ablation and chemotherapy. After a comprehensive literature review, an expert panel rated appropriateness of each treatment option for a total of 1,872 ratings decisions in 252 cases. A decision model was constructed, consensus measured and results validated using 48 virtual cases, and 34 real cases with known outcomes. Results Consensus was achieved with overall agreement rates of 93.4 to 99.1%. Absolute resection contraindications included unresectable extrahepatic disease, more than 70% liver involvement, liver failure, and being surgically unfit. Factors not influencing treatment strategy were age, primary tumor stage, timing of metastases detection, past blood transfusion, liver resection type, pre-resection carcinoembryonic antigen (CEA), and previous hepatectomy. Immediate resection was appropriate with adequate radiologically-defined resection margins and no portal adenopathy; other factors included presence of ≤ 4 or > 4 metastases and unilobar or bilobar involvement. Resection was appropriate postchemotherapy, independent of tumor response in the case of ≤ 4 metastases and unilobar liver involvement. Resection was appropriate only for > 4 metastases or bilobar liver involvement, after tumor shrinkage with chemotherapy. When possible, resection was preferred to local ablation. Conclusion The results were incorporated into a decision matrix, creating a computer program (OncoSurge). This model identifies individual patient resectability, recommending optimal treatment strategies. It may also be used for medical education.
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
Dy, Grace K. , Thomas, James P. , Wilding, George, Bruzek, Laura M., Mandrekar, Sumithra J. , Erlichman, Charles , Alberti, Dona, Binger, Kim, Pitot, Henry C., Hanson, Lorelei J., Marnocha, Rebecca, Tutsch, Kendra D., Adjei, Alex A. , Alberts, Steven R. , Kaufmann, Scott H.

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 9 | Pages: 3410-3416

10.1158/1078-0432.ccr-04-2068 | PMID 15867242 Get It

Abstract Purpose: To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced malignancies. Patients and Methods: Twenty-eight patients (14 male and 14 female) received PS-341 twice weekly for 4 of 6 weeks (schedule I). Because toxicity necessitated dose omissions on this schedule, 16 additional patients (12 male and 4 female) received PS-341 twice weekly for 2 of every 3 weeks (schedule II). A total of 73 courses of treatment was given (median, 2; range, 1-4). Inhibition of 20S proteasome activity in peripheral blood mononuclear cells (PBMC) and accumulation of proteasome-targeted polypeptides in tumor tissue were evaluated as pharmacodynamic markers of PS-341 activity. Results: The most common toxicity was thrombocytopenia, which was dose limiting at 1.7 mg/m2 (schedule I) and 1.6 mg/m2 (schedule II), respectively. Sensory neuropathy was dose-limiting in a patient in schedule I. Grade ≥3 toxicities for schedule I were constipation, fatigue, myalgia, and sensory neuropathy. Grade ≥3 toxicities for schedule II were dehydration resulting from diarrhea, nausea and vomiting, fatigue, hypoglycemia, and hypotension. The maximum tolerated dose was 1.5 mg/m2 for both schedules. Reversible dose-dependent decreases in 20S proteasome activity in PBMCs were observed, with 36% inhibition at 0.5 mg/m2, 52% at 0.9 mg/m2, and 75% at 1.25 mg/m2. Accumulation of proteasome-targeted polypeptides was detected in tumor samples after treatment with PS-341. A patient with multiple myeloma had a partial response. Conclusion: PS-341 given 1.5 mg/m2 twice weekly for 2 of every 3 weeks is well tolerated and should be further studied.
In Reply
Sargent, Daniel J. , Loprinzi, Charles L. , Alberts, Steven R. , Gill, Sharlene , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | January 19, 2005 | Volume: 23 | Issue: 3 | Pages: 654-655

10.1200/jco.2005.05.260 Get It

Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial
Erlichman, Charles , Steen, Preston D. , Foster, Nathan R. , Moore, Dennis F., Rowland, Kendrith M. , Nair, Suresh , Tschetter, Loren K., Fitch, Tom R., Alberts, Steven R. , Schroeder, Mark A.

Mayo Clinic

Journal of Clinical Oncology | December 21, 2004 | Volume: 22 | Issue: 24 | Pages: 4944-4950

10.1200/jco.2004.05.034 | PMID 15611509 Get It

Purpose Gemcitabine remains the standard therapy for metastatic pancreatic adenocarcinoma (ACA), but has limited activity. ISIS-2503 is an antisense compound directed against H-ras with preclinical activity against pancreatic ACA in tumor models. The combination of ISIS-2503 and gemcitabine has been evaluated in a prior phase I study. Methods Patients with metastatic or locally advanced pancreatic ACA not amenable to surgery or local radiation received gemcitabine 1,000 mg/m2 intravenously over 30 minutes on days 1 and 8 and ISIS-2503 6 mg/kg/d as a continuous intravenous infusion over 14 days of an every-3-weeks cycle. Responses were monitored by radiologic imaging every 6 weeks. Results Forty-eight eligible patients were enrolled, 43 with metastatic disease. Median follow-up was 12.6 months (range, 2.2 to 16.8 months) for living patients. A median of four cycles of treatment was given (range, 1 to 18 cycles). All patients were assessable for response and toxicity. The 6-month survival percentage was 57.5% (95% CI, 44.9% to 73.5%) and the median survival was 6.6 months. The response rate was 10.4% (one complete response, four partial responses). Clinically significant toxicity was limited except for one fatal pulmonary embolism. Conclusion This study shows a promising response rate to the combination of gemcitabine and ISIS-2503 in patients with pancreatic ACA. The observed 6-month survival rate in these patients met our protocol-defined criteria for success. This regimen is tolerable, but is of unclear benefit. Additional studies evaluating the role of gemcitabine and ISIS-2503 in the treatment of pancreatic ACA should be considered.